Tandem Diabetes Care (TNDM) EBIT Margin (2013 - 2026)
Tandem Diabetes Care (TNDM) posted EBIT Margin of 7.05% for Q1 2026, down 346.9% on a QoQ basis from 2.86% in Q4 2025, and up 4451.0% year-over-year from 0.15% in Q1 2025.
Tandem Diabetes Care (TNDM) EBIT Margin (2013 - 2026) Analysis & Trends
Tandem Diabetes Care's EBIT Margin history runs 14 years deep, the most recent figure standing at 7.05% for Q1 2026.
- Quarterly EBIT Margin rose 4451.0% year-over-year to 7.05% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.16% (up 999.0% YoY) and the FY2025 annual result came in at 18.45%, down 791.0% from the prior year.
- EBIT Margin was 7.05% for Q1 2026 at Tandem Diabetes Care, down from 2.86% in the prior quarter.
- Across five years, EBIT Margin topped out at 2.86% in Q4 2025 and bottomed at 75.46% in Q1 2023.
- A 5-year average of 18.19% and a median of 13.87% in 2024 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin plunged 6674 bps — and 2024, when it surged 5372 bps.
- Tandem Diabetes Care's EBIT Margin stood at 8.06% in 2022, then sank by 121 bps to 17.82% in 2023, then jumped by 99 bps to 0.21% in 2024, then jumped by 1490 bps to 2.86% in 2025, then tumbled by 347 bps to 7.05% in 2026.
- Business Quant data shows TNDM's EBIT Margin at 7.05% in Q1 2026, 2.86% in Q4 2025, and 9.17% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Tandem Diabetes Care | 1.16 Bn | 587.46 Mn | 136.79 Mn | -7.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.05% |
| Dec 31, 2025 | 2.86% |
| Sep 30, 2025 | -9.17% |
| Jun 30, 2025 | -21.53% |
| Mar 31, 2025 | -51.56% |
| Dec 31, 2024 | -0.21% |
| Sep 30, 2024 | -10.70% |
| Jun 30, 2024 | -13.87% |
| Mar 31, 2024 | -21.74% |
| Dec 31, 2023 | -17.82% |
| Sep 30, 2023 | -16.99% |
| Jun 30, 2023 | -19.81% |
| Mar 31, 2023 | -75.46% |
| Dec 31, 2022 | -8.06% |
| Sep 30, 2022 | -23.22% |
| Jun 30, 2022 | -6.11% |
| Mar 31, 2022 | -8.72% |
| Dec 31, 2021 | 6.07% |
| Sep 30, 2021 | 4.30% |
| Jun 30, 2021 | 3.16% |